Marker composition for cancer diagnosis or prognosis based on exosome overexressing gcc2
AssigneeKorea University Research and Business Foundation
InventorsHyun Koo Kim, Byeong Hyeon Choi, Yuhua Quan, Jiyun Rho
Life of this patent
Estimating the term…
Abstract
Provided according to one embodiment of the present invention is a marker composition for diagnosis or prognosis of esophageal cancer or thymic carcinoma, comprising an exosome overexpressing GRIP and coiled-coil domain-containing protein 2 (GCC2).
Claims12
A marker composition for diagnosing or predicting prognosis of thymic cancer, the composition comprising an exosome overexpressing a GRIP and coiled-coil domain-containing protein (GCC2) protein.
A composition for diagnosing or predicting prognosis of thymic cancer, the composition comprising a primer or probe that specifically binds to a GRIP and coiled-coil domain-containing protein (GCC2) gene in an exosome.
A composition for diagnosing or predicting prognosis of thymic cancer, the composition comprising an antibody that specifically binds to a GRIP and coiled-coil domain-containing protein (GCC2) protein in an exosome.
-8. (canceled)
A method for providing information necessary for diagnosing thymic cancer or predicting a prognosis thereof, the method comprising steps of:
- (a) separating an exosome from a biological sample isolated from a subject;
- and
- (b) measuring an expression level of a GRIP and coiled-coil domain-containing protein (GCC2) gene or protein in the exosome.
(canceled)
A method for screening a therapeutic agent for thymic cancer, the method comprising steps of:
- (a) treating a candidate substance for the therapeutic agent for thymic cancer in a biological sample isolated from a patient with thymic cancer;
- (b) separating an exosome from the biological sample;
- and
- (c) measuring an expression level of a GRIP and coiled-coil domain-containing protein (GCC2) gene or protein in the exosome.
Dependencies are inferred from the claim text.